Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Boehringer Ingelheim63,127 enrolled

Overview

As part of the post-marketing surveillance, information is to be gathered regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice

Study Type

OBSERVATIONAL

Enrollment

63,127

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Tiotropium bromideDRUG

Tiotropium bromide18 micrograms (capsule with powder for inhalation)

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women aged at least 40 years presenting with the symptoms of COPD Exclusion Criteria: * Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information

Outcomes

Primary Outcomes

Change from baseline in breathlessness when walking/climbing stairs

Time frame: Baseline, after 4 weeks

Change from baseline in overall severity of the clinical picture

Time frame: Baseline, after 4 weeks of treatment

Occurrence of Adverse Events

Time frame: up to 4 weeks

Change from baseline in breathlessness on Physical exercise

Time frame: Baseline, after 4 weeks

Change from baseline in breathlessness during housework

Time frame: Baseline, after 4 weeks

Change from baseline in breathlessness during everyday activities

Time frame: Baseline, after 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.